SLN — Silence Therapeutics Share News
0.000.00%
Last trade - 00:00- $928.86m
- $856.81m
- $0.56m
Brief: Silence Therapeutics To Be Acquired By Merck KGaA
NASDAQ RESUMED AT 08:45 AM
Germany's Merck buys Silence Therapeutics in $1.3 billion RNA drug deal (updated)
Germany's Merck buys Silence Therapeutics for $1.3 billion
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
Silence Therapeutics dips premarket after $175 mln share sale
Brief: Silence Therapeutics Announces Pricing Of Upsized $175 Million Underwritten Public Offering
Silence Therapeutics jumps after mid-stage trial data for blood cancer drug
Brief: Silence Therapeutics Reports Second Quarter 2025 Financial Results And Recent Business Highlights
Brief: Silence Therapeutics files for stock shelf, size not disclosed
Brief: Silence Therapeutics Announces Positive Results From Ongoing Sanreco Phase 1 Study
Brief: Silence Therapeutics Announces Positive Topline 48-Week Data From Phase 2 Study Of Zerlasiran In Patients With Elevated Lipoprotein
Brief: Silence Therapeutics PLC Files For Resale Of Up To 5.71 Million Shares By The Selling Securityholders - SEC Filing
Brief: Silence Therapeutics Announces Positive 36-Week Data From Ongoing Phase 2 Study Of Zerlasiran In Patients With High Lipoprotein(A)
Brief: Silence Therapeutics Receives $10 Million Milestone Payment From AstraZeneca Collaboration
Brief: Silence Therapeutics Achieves $10 Million Milestone Payment From Astrazeneca Collaboration
Brief: Silence Therapeutics Announces Preliminary Single Dose Results From SLN124 Phase 1 Study In Patients With Thalassemia
Brief: Silence Therapeutics Announces FDA Fast Track Designation For Sln124, A Novel Investigational Sirna Therapy For The Treatment Of Polycythemia Vera
NASDAQ RESUMED AT 10:32 AM